Evidence map›Paper›PMID 42711491›Full record

ArticleNature chemical biology2026

Chemogenomic maps reveal a PRDX1-dependent iron-damage axis in the DNA damage response.

Thomas A O'Loughlin, Abolfazl Arab, Sara Misiukiewicz, Elizabeth Montesano, Christopher Yogodzinski, Ashir A Borah, Valentina Quarantotti, Kevin Lou, Barry S Rosen, Jacob E Corn and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Thomas A O'Loughlin *Department of Urology, University of California, San Francisco, CA, USA. thomas.oloughlin@mssm.edu.ORCID http://orcid.org/0000-0002-4783-2352
Abolfazl Arab *Department of Urology, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-0024-2937
Sara MisiukiewiczDepartment of Urology, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2021-1713
Elizabeth MontesanoDepartment of Urology, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-0073-7526
Christopher YogodzinskiDepartment of Urology, University of California, San Francisco, CA, USA.
Ashir A BorahDepartment of Urology, University of California, San Francisco, CA, USA.
Valentina QuarantottiDiscovery Sciences, Biopharma R&D, AstraZeneca, Cambridge, UK.
Kevin LouQuantitative Biosciences Institute, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4939-4381
Barry S RosenDiscovery Sciences, Biopharma R&D, AstraZeneca, Cambridge, UK.
Jacob E CornInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7798-5309
Davide GianniDiscovery Sciences, Biopharma R&D, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0009-0005-6051-8201
Shaheen KabirDepartment of Urology, University of California, San Francisco, CA, USA. shaheen.kabir@gmail.com.ORCID http://orcid.org/0000-0002-9035-1124
Josep V FormentBioscience, Oncology R&D, AstraZeneca, Cambridge, UK. josep.forment@astrazeneca.com.ORCID http://orcid.org/0000-0002-7797-2583
Luke A GilbertDepartment of Urology, University of California, San Francisco, CA, USA. luke@arcinstitute.org.ORCID http://orcid.org/0000-0001-5854-0825

Funding

Spatial multiomic mapping of gene function with CRISPRoffUM1HG012660 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Luke Gilbert · 2022 to 2026
$8.2M
A GENETIC INTERACTION MAP OF THE HUMAN NUCLEUSDP2CA239597 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GILBERT, LUKE · 2018 to 2018
$2.4M
Cancer Research UK (CRUK) CGCATF-2021/100006Cancer Research UK (CRUK) OT2CA278665EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 855741U.S. Department of Health & Human Services | National Institutes of Health (NIH) DP2CA239597U.S. Department of Health & Human Services | National Institutes of Health (NIH) UM1HG012660
6 · The paper itself

Abstract

The DNA damage response (DDR) is a sophisticated network of cellular pathways whose perturbation leads to genome instability and is a key hallmark of oncogenesis. Here, we present data from 32 genome-scale loss-of-function CRISPR interference chemical-genetic screens with inhibitors targeting core constituents of the DDR machinery (PARP, ATR, ATM, DNAPK and WEE1), as both single agents and in combination with poly(ADP-ribose) polymerase inhibitors. These experiments identify >1,000 genes whose perturbation modifies the DDR and provides a rich resource to the DDR community. In addition, this compendium of functional genomics data reveals key principles governing the DDR and highlights a strong chemical-genetic interaction between loss of activity of the peroxiredoxin PRDX1 and all tested DDR inhibitors through a mechanism involving iron availability mediated by an MRGBP-PAX7-IREB2 axis. Our data position PRDX1 as a key suppressor of DNA damage accumulation and potential druggable target in combination with DDR inhibitors.

Identifiers

PMID42711491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.